SHORT-TERM INVESTMENTS AND FAIR VALUE MEASUREMENTS

12 Months Ended

Jul. 31, 2026

Short-term Investments And Fair Value Measurements

SHORT-TERM INVESTMENTS AND FAIR VALUE MEASUREMENTS

NOTE 8: SHORT-TERM INVESTMENTS AND FAIR VALUE MEASUREMENTS

Short-term investments

Short-term investment activity for the years ended July 31, 2026 and 2025 was as follows:

	2026			2025
	Year ended July 31,
	2026			2025
Balance, beginning of year	$	7,372,473		$	-
Purchases of short-term investments		24,590,000			7,316,000
Proceeds from short-term investments		(21,289,000	)		-
Unrealized gain on short-term investments		14,804			56,473
Balance, end of year	$	10,688,277		$	7,372,473

During the years ended July 31, 2026 and 2025, the Company recognized unrealized gains on short-term investments of $14,804 and $56,473, respectively, which are included in financial income, net. There were no realized gains or losses on short-term investments during either period.

Fair value measurements

The following table presents information about our financial instruments that are measured at fair value on a recurring basis as of July 31, 2026 and 2025:

	Fair Value Measurements at
	July 31, 2026						July 31, 2025
	Level 1		Level 3		Total		Level 1		Level 3		Total
Financial Assets:
Short-term investments		10,688,277		-		10,688,277		7,372,473		-		7,372,473
Total assets measured at fair value	$	10,688,277	$	-	$	10,688,277	$	7,372,473	$	-	$	7,372,473

Financial liabilities:
Warrants liability	$	-	$	38,939	$	38,939	$	151,586	$	186,086	$	337,672
Total liabilities measured at fair value	$	-	$	38,939	$	38,939	$	151,586	$	186,086	$	337,672

BriaCell Therapeutics Corp

Notes to the Consolidated Financial Statements

For the Years Ended July 31, 2026 and 2025

(Expressed in US Dollars, unless otherwise indicated)

NOTE 8: SHORT-TERM INVESTMENTS AND FAIR VALUE MEASUREMENTS (Cont.)

The Company classifies its short-term investments and the liability in respect of publicly traded warrants within Level 1 because they are valued using the quoted market prices in active markets. The Company holds level 1 short term investments with coupon rates ranging between 1.11% to 5.50%.

The fair value of the warrant liability for non-public warrants is measured using significant unobservable inputs, including historical volatility, and thus is classified as a Level 3 financial instrument. There were no transfers between levels of the fair value hierarchy during the years ended July 31, 2026 and 2025.